Benign%20prostatic%20hyperplasia Management

Management

Follow Up

Patients on watchful waiting should be assessed at 6 months and then annually, provided that there are no absolute indications for surgery and symptoms do not deteriorate
Patients on pharmacological therapy should be assessed to determine response to treatment and safety
- Patients taking alpha blockers, anticholinergics, beta-3 adrenergic agonist, PDE5 inhibitors or combination therapy should be assessed at 4-6 weeks after drug initiation and then every 6-12 months thereafter
- Patients taking 5-alpha reductase inhibitors should be assessed at 3-6 months after drug initiation and then every 6-12 months thereafter
  - Patients on 5-alpha reductase inhibitors should be monitored with annual DRE and PSA
Patients who underwent surgical therapy should be assessed 4-6 weeks after catheter removal to evaluate for treatment response and adverse events
- No further reassessment is necessary in patients without adverse events and with symptomatic relief

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.